Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Uterine Neoplasms 1 Smoking 1 Rectal Neoplasms 1 Pulmonary Disease, Chronic Obstructive 1 Pregnancy Complications 1 Nasopharyngeal Neoplasms 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Leiomyoma 1 Infertility, Female 1 Genetic Diseases, Inborn 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Dexamethasone 117 Lenalidomide 77 daratumumab 59 Bortezomib 54 carfilzomib 41 Calcium Dobesilate 36 pomalidomide 35 Cyclophosphamide 27 isatuximab 23 belantamab mafodotin 22 Specimen Handling 20 Biopsy 20 Magnetic Resonance Spectroscopy 17 dexamethasone acetate 13 dexamethasone 21-phosphate 13 auricularum 12 Melphalan 12 selinexor 11 ixazomib 11 iberdomide 11 fludarabine 11 elotuzumab 11 fludarabine phosphate 8 talquetamab 7 X-Rays 7 trametinib 6 nirogacestat 6 venetoclax 5 Thalidomide 5 Nuclear Medicine Department, Hospital 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Multiple Myeloma × Tablets × Clear all

NCT04717700 2025-03-18

SABLe

Odense University Hospital

Phase 2 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡